Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Lung Cancer
77%
Epidermal Growth Factor Receptor
51%
Chemoradiotherapy
44%
Lung Transplantation
36%
Recurrent Disease
30%
Cancer Cell
28%
Lobectomy
27%
Metastatic Carcinoma
24%
Lung Adenocarcinoma
24%
Overall Survival
23%
Neoplasm
23%
Lymphocyte
20%
Neutrophil
20%
Lung
20%
Prognostic Factor
19%
Malignant Neoplasm
18%
Surgery
15%
Afatinib
15%
Bronchopleural Fistula
13%
Allograft
12%
Mesenchymal-Epithelial Transition
12%
microRNA
12%
Computer Assisted Tomography
12%
Osimertinib
12%
Tyrosine-Kinase Inhibitor
11%
Segmentectomy
11%
Methylation
11%
Stomach Cancer
10%
Bronchiolitis Obliterans
10%
Lymph Node
10%
Epidermal Growth Factor Receptor 2
10%
Gamma Urogastrone
10%
Small Cell Lung Cancer
10%
Cancer Associated Fibroblast
10%
Living Donor
10%
Drug Resistance
9%
Lymph Node Metastasis
9%
Lung Metastasis
8%
Video-Assisted Thoracoscopic Surgery
8%
Adverse Event
8%
Pneumonectomy
8%
Cancer Growth
8%
Non-Small Cell Lung Cancer
8%
Division
8%
Cancer Surgery
7%
Cell Line
7%
Recurrence Free Survival
7%
Targeted Therapy
7%
Postoperative Complication
7%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
97%
Epidermal Growth Factor Receptor
68%
Lung Cancer
62%
Lung Adenocarcinoma
45%
Malignant Neoplasm
42%
Neoplasm
41%
Chemoradiation Therapy
33%
Gamma Urogastrone
22%
Epidermal Growth Factor Receptor 2
22%
Pleura Mesothelioma
21%
Overall Survival
20%
Drug Resistance
19%
Epidermal Growth Factor Receptor Kinase Inhibitor
18%
Breast Cancer
16%
microRNA
16%
Afatinib
15%
Recurrent Disease
15%
Metastasis
13%
Cancer Growth
13%
Chemotherapy
12%
Lymph Node Metastasis
12%
Protein Tyrosine Kinase Inhibitor
12%
Monoclonal Antibody
11%
CD146 Antigen
11%
Stomach Cancer
10%
Transcription Factor RUNX2
10%
Heat Shock Protein 90 Inhibitor
10%
Luminespib
10%
Trastuzumab
10%
Glycoprotein
10%
Reperfusion Injury
10%
Histidine
10%
Disease
9%
Mouse
9%
Protein Tyrosine Kinase
8%
Cytokine
8%
Mouse Model
7%
Inflammation
7%
Fibrosis
7%
Recurrence Free Survival
6%
Lung Fibrosis
6%
Neratinib
6%
Cisplatin
6%
Docetaxel
6%
Osimertinib
6%
Crizotinib
6%
Drug Repositioning
6%
Melanoma
5%
Primary Graft Dysfunction
5%
Circulating microRNA
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
23%
EGFR mutation
22%
Epidermal Growth Factor Receptor
19%
Lung Transplantation
18%
Lung Adenocarcinoma
18%
Induction Chemoradiotherapy
16%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
15%
Drug Resistance
15%
Malignant Pleural Mesothelioma
15%
Overall Survival
12%
Japan
11%
Chemoradiotherapy Followed by Surgery
11%
Prognostic Impact
10%
Circulating DNA
10%
Cancer Progression
10%
Neutrophil-to-lymphocyte Ratio
10%
Genetic Loci
10%
Renal Disease
10%
Hsp90 Inhibitor
10%
Ethnic-specific
10%
SNP Array
10%
Periostin (POSTN)
10%
Cancer Drugs
10%
YES1
10%
Cancer-associated Fibroblasts
10%
Real-time Database
10%
Database Study
10%
Surgical Outcomes
10%
Lung Cancer Patients
10%
Ischemia-reperfusion Injury
9%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
9%
AUY922
9%
Lung
8%
Postoperative Complications
7%
Adjuvant Therapy
7%
Acquired Resistance
7%
Osimertinib
6%
Lung Cancer
6%
Pulmonary Resection
6%
Epithelial-mesenchymal Transition
6%
Living-donor Lobar Lung Transplantation (LDLLT)
6%
MicroRNA-34a (miR-34a)
6%
Combined Modality Therapy
6%
Therapeutic Target
5%
Lymph Node Station
5%
Anatomical Resection
5%
Gross Total Resection
5%
Early-stage Lung Adenocarcinoma
5%
Chemoradiotherapy
5%
After Surgery
5%
